Key terms
About DXCM
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DXCM news
Apr 30
5:01am ET
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)
Apr 30
3:31am ET
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)
Apr 26
12:09pm ET
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
Apr 26
9:14am ET
DexCom price target raised to $160 from $151 at Raymond James
Apr 26
8:21am ET
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)
Apr 26
7:51am ET
Dexcom (DXCM) Gets a Buy from Piper Sandler
Apr 26
7:47am ET
Dexcom (DXCM) Gets a Buy from Stifel Nicolaus
Apr 26
7:45am ET
DexCom price target raised to $145 from $144 at Canaccord
Apr 26
6:42am ET
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
Apr 26
5:50am ET
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)
Apr 26
5:45am ET
Dexcom’s Strong Q1 Performance and Upbeat 2024 Outlook Justify Buy Rating
Apr 25
4:05pm ET
DexCom raises FY24 revenue view to $4.2B-$4.35B from $4.15B-$4.35B
Apr 25
4:04pm ET
DexCom reports Q1 adjusted EPS 32c, consensus 27c
Apr 25
3:11pm ET
DexCom options imply 5.8% move in share price post-earnings
Apr 25
1:09pm ET
Notable companies reporting after market close
Apr 17
3:59am ET
RBC Capital Keeps Their Buy Rating on Dexcom (DXCM)
Apr 15
7:35am ET
DexCom price target raised to $156 from $150 at BTIG
Apr 03
9:06am ET
DexCom publishes annual sustainability report
Apr 03
5:51am ET
DexCom price target raised to $161 from $148 at Citi
Mar 26
4:47am ET
Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)
Mar 25
9:56am ET
Early notable gainers among liquid option names on March 25th
Mar 18
5:55am ET
TipRanks’ ‘Perfect 10’ List: Analysts Pound the Table on These Top-Scoring Stocks
Mar 12
9:51am ET
Oracle, Dollar General upgraded: Wall Street’s top analyst calls
Mar 12
6:28am ET
RBC starts DexCom with Outperform on multi-year runway
Mar 12
5:25am ET
Wells Fargo Remains a Buy on Dexcom (DXCM)
Mar 12
5:05am ET
DexCom initiated with an Outperform at RBC Capital
Mar 11
1:10am ET
Analysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Dexcom (DXCM)
Mar 06
9:55am ET
Early notable gainers among liquid option names on March 6th
Mar 06
7:35am ET
Piper Sandler Sticks to Its Buy Rating for Dexcom (DXCM)
Mar 06
6:27am ET
Dexcom’s Stelo Launch Fuels Buy Rating on Expansive Market Opportunity
Mar 06
6:02am ET
DexCom’s (NASDAQ:DXCM) Stelo Becomes the First Glucose Monitor to be Cleared for OTC Use
No recent press releases are available for DXCM
DXCM Financials
Key terms
Ad Feedback
DXCM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DXCM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range